Returning guest, Dr. Jeffrey Cohen, Nephrologist with the Cleveland Clinic, a renowned leader in Multiple Sclerosis research and President of ACTRIMS, the world’s largest conference focused on MS research, discusses highlights from the 8th Joint ACTRIMS-ECTRIMS (the European counterpart) Conference (MSVirtual2020). He talks about advancements in therapeutics, outcomes of clinical trials, and the impact of COVID on clinical research and patient care.
ACTRIMS President, Jeffrey A. Cohen, M.D.
Dr. Cohen is Professor of Medicine (Neurology) in the Cleveland Clinic Lerner College of Medicine. He received a BA from Connecticut College in 1976 and an MD from the University of Chicago School of Medicine in 1980. He completed a Neurology Residency in 1984 then a Post-doctoral Research Fellowship in Neuroimmunology in 1987, both at the University of Pennsylvania. Dr. Cohen has worked at the Mellen MS Center at the Cleveland Clinic since 1994 and became Director in 2014. He also is Director of the Experimental Therapeutics Program, the Clinical Neuroimmunology Fellowship, and the MS Academic Coordinating Center. Dr. Cohen has a large clinical practice devoted primarily to the care of patients with MS and related disorders. He has over 200 publications concerning immunologic, imaging, and clinical aspects of MS. He has been involved in various capacities in a large number of clinical trials of potential therapies for MS.